SCHEMBL4091327

SCHEMBL4091327

BrCSCc1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
TRPA1 O75762 1/20 0.50
TSHR P16473 1/20 0.50
CYP2C19 P33261 2/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
IDO1 P14902 3/20 0.43
NOS3 P29474 1/20 0.43
NOS1 P29475 1/20 0.43
NOS2 P35228 1/20 0.43
MAOB P27338 1/20 0.42
POLB P06746 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CALM1 P0DP23 1/20 0.41
HPGD P15428 1/20 0.40
CTSL P07711 1/20 0.40
CTSB P07858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11465830 0.83 CYP2C19 (0.56) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL206 0.83 CYP2C19 (0.56) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5209412 0.80 CYP2C19 (0.54) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL7136112 0.80 CYP2C19 (0.54) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5209418 0.80 CYP2C19 (0.54) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4093220 0.80 CYP2C19 (0.55) ALDH1A1TRPA1TSHRCYP2C19CYP1A2
SCHEMBL8541503 0.78 CYP2C19 (0.52) ALDH1A1CYP2C19CYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL7138153 0.78 CYP2C19 (0.56) CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL3078147 0.78 CYP2C19 (0.64) ALDH1A1CYP2C19CYP1A2CYP3A4CYP2D6
SCHEMBL6042549 0.77 CYP2C19 (0.52) ALDH1A1TRPA1TSHRCYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221640-A1 Novel Crystal Modifications ASTRAZENECA AB (SE) 2009-09-03 US disclosed
US-20090221640-A1 Novel Crystal Modifications ASTRAZENECA AB (SE) 2009-09-03 US disclosed
EP-2064202-A2 A NEW CRYSTALLINE FORM G OF (5S)-5-[4-(5-CHLORO-PYRIDIN-2-YLOXY)-PIPERIDINE-1-SULFONYL-METHYL]-5-METHYL-IMIDAZOLIDINE-2,4-DIONE (I) AND INTERMEDIATES THEREOF. AstraZeneca AB (SE) 2009-06-03 EP disclosed
CN-101448819-A A new crystalline form g of (5s)-5-[4-(5-chloro-pyridin-2-yloxy)-piperidine-1-sulfonylmethyl]-5-methyl-imidazolidine-2,4-dione (i) and intermediates thereof ASTRAZENECA AB (SE) 2009-06-03 CN disclosed
WO-2007106022-A2 A NEW CRYSTALLINE FORM G OF (5S) -5- [4- (5-CHLORO-PYRIDIN-2- YLOXY) -PIPERIDINE-1-SULFONYLMETHYL] - 5 -METHYL -IMIDAZOLIDINE - 2,4-DIONE (I) AND INTERMEDIATES THEREOF. ASTRAZENECA AB (SE) 2007-09-20 WO disclosed
US-7071175-B1 Pyridine mercapto carboxylic acids as carboxypeptidase U inhibitors ASTRAZENECA AB (SE) 2006-07-04 US disclosed
EP-1180098-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2002-02-20 EP disclosed
WO-2000066557-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2000-11-09 WO disclosed
EP-0662952-B1 PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF 3-SUBSTITUTED 2-SULPHONYL METHYL PROPIONIC ACIDS AND INTERMEDIATE PRODUCTS HOECHST AG (DE) 1999-08-25 EP disclosed
US-5856322-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, CARDIOVASCULAR DISORDERS MERCK FROSST CANADA, INC. (CA) 1999-01-05 US disclosed
WO-1994007849-A1 PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF 3-SUBSTITUTED 2-THIOMETHYL PROPIONIC ACIDS HOECHST AKTIENGESELLSCHAFT (DE) 1994-04-14 WO disclosed
WO-1994007850-A1 PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF 3-SUBSTITUTED 2-SULPHONYL METHYL PROPIONIC ACIDS AND INTERMEDIATE PRODUCTS HOECHST AKTIENGESELLSCHAFT (DE) 1994-04-14 WO disclosed
US-5270324-A Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists MERCK FROSST CANADA, INC. (CA) 1993-12-14 US disclosed
US-5223516-A Endopeptidase inhibitors E. R. SQUIBB & SONS, INC. (US) 1993-06-29 US disclosed
US-5202321-A Antihistamine, antiallergens, antiinflammatory agents MERCK FROSST CANADA, INC. (CA) 1993-04-13 US disclosed
EP-0518426-A1 Thiopyrano (2,3,4-c,d) indoles as inhibitors of leukotriene biosynthesis MERCK FROSST CANADA INC. (CA) 1992-12-16 EP disclosed
EP-0480717-A1 Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists MERCK FROSST CANADA INC. (CA) 1992-04-15 EP disclosed
EP-0449523-A1 Mercapto- or acylthio-trifluoromethyl amide derivatives and their use E.R. SQUIBB & SONS, INC. (US) 1991-10-02 EP disclosed
US-4552889-A INHIBITS ANGIOTENSINASE ELI LILLY AND COMPANY (US) 1985-11-12 US disclosed
EP-0128728-A1 Angiotensinase inhibitors ELI LILLY AND COMPANY (US) 1984-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221640-A1 Novel Crystal Modifications PTMS, NT5C, CDK5 ALDH1A1 1028/4885TRPA1 4844/4885TSHR 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.